Evidence map›Paper›PMID 33843586›Full record

ArticleeLife2021

Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth.

Deniz Cizmeci, Giuseppe Lofano, Evan Rossignol, Anne-Sophie Dugast, Dongkyoon Kim, Guy Cavet, Ngan Nguyen, Yann Chong Tan, Michael S Seaman, Galit Alter and 1 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Deniz CizmeciRagon Institute of MGH, MIT and Harvard, Cambridge, United States.
Giuseppe LofanoRagon Institute of MGH, MIT and Harvard, Cambridge, United States.
Evan RossignolRagon Institute of MGH, MIT and Harvard, Cambridge, United States.
Anne-Sophie DugastRagon Institute of MGH, MIT and Harvard, Cambridge, United States.
Dongkyoon KimAtreca Inc, Redwood City, United States.
Guy CavetAtreca Inc, Redwood City, United States.
Ngan NguyenAtreca Inc, Redwood City, United States.
Yann Chong TanAtreca Inc, Redwood City, United States.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, United States.
Galit AlterRagon Institute of MGH, MIT and Harvard, Cambridge, United States.
Boris JulgRagon Institute of MGH, MIT and Harvard, Cambridge, United States.ORCID 0000-0002-4687-9626
Ragon Institute of MGH, MIT and Harvard · USBeth Israel Deaconess Medical Center · US

Funding

Bill and Melinda Gates Foundation OPP1066973Bill and Melinda Gates Foundation OPP1146996Ragon Institute of MGH, MIT and Harvard Internal funds
6 · The paper itself

Abstract

A minor subset of individuals infected with HIV-1 develop antibody neutralization breadth during the natural course of the infection, often linked to chronic, high-level viremia. Despite significant efforts, vaccination strategies have been unable to induce similar neutralization breadth and the mechanisms underlying neutralizing antibody induction remain largely elusive. Broadly neutralizing antibody responses can also be found in individuals who control HIV to low and even undetectable plasma levels in the absence of antiretroviral therapy, suggesting that high antigen exposure is not a strict requirement for neutralization breadth. We therefore performed an analysis of paired heavy and light chain B-cell receptor (BCR) repertoires in 12,591 HIV-1 envelope-specific single memory B-cells to determine alterations in the BCR immunoglobulin gene repertoire and B-cell clonal expansions that associate with neutralizing antibody breadth in 22 HIV controllers. We found that the frequency of genomic mutations in IGHV and IGLV was directly correlated with serum neutralization breadth. The repertoire of the most mutated antibodies was dominated by a small number of large clones with evolutionary signatures suggesting that these clones had reached peak affinity maturation. These data demonstrate that even in the setting of low plasma HIV antigenemia, similar to what a vaccine can potentially achieve, BCR selection for extended somatic hypermutation and clonal evolution can occur in some individuals suggesting that host-specific factors might be involved that could be targeted with future vaccine strategies.

Indexed as

Clonal EvolutionAdultB-LymphocytesBroadly Neutralizing AntibodiesFemaleHIV-1HIV InfectionsHumansMaleMiddle AgedUnited StatesBroadly Neutralizing Antibodiesb-cell evolutionBCR repertoirecell biologyHIV infectionhumaninfectious diseasemicrobiologyneutralizing antibodies

Identifiers

PMID33843586
PMCPMC8041465
OpenAlexW3153195978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.